Clinical trials: TPF
Cancer
Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer
1.To compare overall survival after treatment with the test tri-therapy (TPF: docetaxel plus cisplatin and 5FU) or the control treatment (PF: cisplatin plus 5-FU) followed by chemoradiotherapy in patients with locally advanced…
- Trial name
- NCT00273546
- Testing
- XRP6976 (Docetaxel/Taxotere)
- Where
- 6 sites in United States, Argentina and 4 more
- Volunteers
- 500 people
- Sponsor
- Sanofi
Head and Neck Neoplasms
Docetaxel in Head and Neck Cancer
Primary Objective: Phase II: To determine the best treatment scheme (TPF vs. PF). Phase III: To compare the time to progression and the treatment failure at the 3 arms. Secondary objectives: To evaluate the safety at the 3 arms.
- Trial name
- NCT00261703
- Testing
- Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy, Cisplatin, 5-fluorouracil (5-FU), radiotherapy, Cisplatin + radiotherapy
- Where
- 2 sites in Portugal, Spain
- Volunteers
- 439 people
- Sponsor
- Sanofi
Head and Neck Neoplasms
Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Patients (SCCHNS)
To evaluate the rate of clinical complete response 6-8 weeks after treatment with docetaxel plus cisplatin and 5-fluorouracil followed by chemoradiotherapy and after chemoradiotherapy alone in patients with locally advanced…
- Trial name
- NCT00357149
- Testing
- Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy, Concomitant cisplatin, 5-FU and radiotherapy
- Where
- Italy
- Volunteers
- 101 people
- Sponsor
- Sanofi